Evidence-Based CardiologySalim Yusuf, John A. Cairns, A. John Camm, Ernest L. Fallen, Bernard J. Gersh John Wiley & Sons, 7 de set. 2011 - 1240 pàgines Evidence based Cardiology was first published in 1998 to universal acclaim. Now, with the move towards more patient focused health care and at the same time increased emphasis on health economics, evidence-based practice is a more important force in health care delivery than ever. This new third edition, written by the world’s leading cardiologists, provides graded evidence-based reviews of the major trials together with recommendations for optimum management, and now includes new grading and recommendation methodology. This is a unique book in the field of cardiology, and the largest evidence based clinical cardiology text. |
Continguts
antithrombotic therapy | |
Ablation therapy for atrial fibrillation | |
Supraventricular tachycardia | |
Prevention and treatment of lifethreatening ventricular | |
Raj S Padwal Arya M Sharma | |
Syncope | |
Cardiopulmonary resuscitation | |
Arrh thmias due to mono enic disorders | |
The application of evidencebased medicine to employment | |
Global perspective on cardiovascular disease | |
Avoidance of worldwide vascular deaths and total deaths | |
achieving smoking | |
Lipids and cardiovascular disease | |
Use of lipidlowering agents in the prevention | |
Blood pressure and cardiovascular disease | |
Dysglycemia and the risk of cardiovascular events | |
Physical activity and exercise in cardiovascular disease | |
Psychosocial factors | |
The social determinants of cardiovascular disease | |
Cardiac risk in those undergoing noncardiac surgery | |
Ethnicity and cardiovascular disease | |
Fetal origins of coronary artery disease | |
Genetics of coronaLy heart disease | |
Molecular genetics of cardiovascular disorders | |
Diet and cardiovascular disease | |
Integrating approaches to prevention of cardiovascular | |
Medical management of stable coronary artery disease | |
Percutaneous intervention | |
Surgical coronary artery revascularization | |
Comparisons of percutaneous coronary intervention | |
Obesity | |
Prehospital management of ST elevation myocardial infarction | |
Early prehospital management of ST segment elevation | |
Antithrombotic therapies for patients with ST segment | |
Complications after myocardial infarction | |
An integrated approach to the management of patients after | |
rhythm and rate control therapies | |
upstream therapies | |
Arrhythmiagenic right ventricular cardiomyopathy | |
management of asymptomatic left ventricular systolic | |
Management of overt heart failure | |
Acute myocarditis and dilated cardiomyopathy | |
Management of hypertrophic cardiomyopathy | |
Infective and infiltrative cardiomyopathies | |
Chagas heart disease | |
Bernard J Gersh Editor | |
indications for surgery | |
Surgical indications in aortic valve disease | |
balloon valvuloplasty | |
mitral valve | |
Valve repair and choice of valve | |
Infective endocarditis | |
Antithrombotic therapy after heart valve replacement | |
Bernard J Gersh and Salim Yusuf Editors | |
Heart disease and pregnancy | |
Arashk Motiei Thoralf M Sundt III Charanjit S Rihal | |
Venous thromboembolic disease | |
Epidemiology | |
References | |
Clinical management of diseases of the aorta | |
indications and postoperative | |
Renal dysfunction | |
Pulmonary hypertension | |
Routine investigations | |
Atrial fibrillation | |
Bradyarrhythmias choice of pacemakers | |
Frases i termes més freqüents
abciximab acute coronary syndromes acute myocardial infarction angiography angioplasty aspirin assessment associated atherosclerosis atrial fibrillation benefit beta-blockers bleeding blood pressure bypass grafting CABG cardiac Cardiology cardiovascular disease cardiovascular risk cholesterol chronic Circulation Class clinical trials clopidogrel cohort compared coronary artery bypass coronary artery disease coronary heart disease death diet dietary dose drug effects elevation Engl enoxaparin Evaluation evidence exercise fibrinolytic follow-up gene genetic glucose guidelines Health heart failure heparin high-risk hospital hypertension improve increased inhibitors intake ischemia ischemic JAm Coll Cardiol JAMA Lancet left ventricular levels lipid major medical therapy meta-analysis mmHg mortality mutations obesity outcomes percutaneous coronary intervention perioperative physical activity placebo plasma platelet population prevention prognosis randomized controlled trials randomized trials rates receptor reduced reperfusion revascularization risk factors serum significant smoking cessation statins STEMI stent strategies stroke surgery thrombolysis tobacco treatment unstable angina vascular versus